The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

CARDIO—AEROBIC ACTIVITIES like walking, running, swimming, and cycling—not only reduces total cholesterol, LDL, vLDL and ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

Scientists are testing the ancient herb borage to see which healing claims hold up and where modern evidence still falls ...

Acute sepsis profoundly changes how intravenous fluids behave within the body. Using a sheep model, researchers investigated ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.